Diabetes is a global health problem. According to data. Premixed Insulin Analogue Compared with Basal-Plus Regimen for Inpatient Glycemic Control
|
|
- Darcy White
- 6 years ago
- Views:
Transcription
1 DIABETES TECHNOLOGY & THERAPEUTICS Volume 18, Number 11, 2016 ª Mary Ann Liebert, Inc. DOI: /dia ORIGINAL ARTICLE Premixed Insulin Analogue Compared with Basal-Plus Regimen for Inpatient Glycemic Control Abraham Edgar Gracia-Ramos, MD, MSc, 1 María del Pilar Cruz-Domínguez, MD, DSc, 2 Eduardo Osiris Madrigal-Santillán, DSc, 3 José Antonio Morales-González, DSc, 3 Eduardo Madrigal-Bujaidar, DSc, 4 and José Leopoldo Aguilar-Faisal, DSc 3 Abstract Background: No previous studies have investigated the use of a premixed insulin analogue in a hospital setting. Objective: To compare the efficacy and safety of treatment with premixed insulin analogue (insulin lispro mix 75/ 25, LM75/25) with the basal-plus regimen with insulin glargine in hospitalized patients with type 2 diabetes (T2D). Materials and Methods: A randomized clinical trial in hospitalized patients with T2D and glucose >140 mg/dl on admission was performed. A total of 54 patients were randomized to receive insulin LM75/25 or glargine. In both groups, a correction dose of lispro was administered before meals. Insulin dose was adjusted to obtain a mean blood glucose (BG) between 100 and 140 mg/dl. Results: Improvement in the mean BG after the first day of treatment was similar in both groups (P = 0.470). Glycemic control at the end of follow-up was similar between the group with insulin LM75/25 ( mg/dl) and insulin glargine ( mg/dl, P = 0.153). The aim of a BG concentration of <140 mg/ dl was obtained in 72% of the patients in the premixed insulin analogue group and 56% of patients in the basalplus group (P = 0.239). There was no difference in the frequency of hypoglycemia between groups (7 vs. 10, P = 0.529). Conclusion: Results of this trial indicate that the use of a premixed insulin analogue is as effective and safe as the basal-plus regimen to achieve glycemic control. Keywords: Hyperglycemia, Inpatient, Insulin lispro mix 75/25, Premixed insulin analogue, Type 2 diabetes. Introduction Diabetes is a global health problem. According to data from the International Diabetes Federation, *382 million people suffer from this disease worldwide. 1 In a hospital setting, it has been estimated that at least 20% of medical and surgical patients present diabetes. 2 Hyperglycemia in hospitalized noncritical patients, both diabetic and nondiabetic, is associated with an increased risk of complications, length of stay, disability, and death Adequate control of blood glucose (BG) level produces a reduction in complications Based on this, the American Diabetes Association (ADA), American Association of Clinical Endocrinologists (AACE), Endocrine Society, American Heart Association (AHA), American Association of Diabetes Educators (AADE), and European Society of Endocrinology and the Society of Hospital Medicine have recommended the treatment of hospital hyperglycemia through insulin administration with the therapeutic goal of maintaining a fasting BG level between 100 and 140 mg/dl and glucose at any time of day <180 md/dl. 16,17 The most recommended insulin application method consists of a basal-bolus regimen. This approach requires subcutaneous administration of basal insulin given once or twice daily in combination with prandial and corrective doses of rapid-action insulin before each meal Several observational and randomized controlled trials in 1 Departamento de Medicina Interna, Hospital de Especialidades, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico. 2 División de Investigación en Salud, Hospital de Especialidades, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico. 3 Laboratorio de Medicina de Conservación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico. 4 Escuela Superior de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico. 705
2
3 PREMIXED INSULIN ANALOGUE IN HOSPITAL SETTING 707 Table 1. Insulin Treatment Protocols (A) Insulin LM75/25 a regimen: Start total daily insulin dose: 0.2 U/kg of body weight when the admission BG concentration is mg/dl 0.3 U/kg of body weight when the admission BG concentration in between 201 and 400 mg/dl Give two-thirds of the total daily dose before breakfast and one-third before dinner (B) Basal-plus regimen with insulin glargine: Start total daily insulin dose: 0.15 U/kg of body weight when the admission BG concentration is mg/dl 0.2 U/kg of body weight when the admission BG concentration in between 201 and 400 mg/dl Give insulin glargine once daily at the same time of the day (C) In both groups: Discontinue oral antidiabetic drugs on admission Supplemental insulin: Give supplemental insulin lispro following the sliding scale protocol for BG >140 mg/dl Insulin adjustment: If mean BG during the day is between 100 and 140 mg/dl in the absence of hypoglycemia: no change If mean BG during the day is between 140 and 180 mg/dl in the absence of hypoglycemia: increase insulin TDD by 10% every day If mean BG during the day is >180 mg/dl in the absence of hypoglycemia: increase insulin TDD by 20% every day If mean BG during the day is between 70 and 99 mg/dl in the absence of hypoglycemia: decrease insulin TDD by 10% every day If a patient develops hypoglycemia (BG <70 mg/ dl), the insulin TDD should be decreased by 20% BG monitoring: Measure BG before each meal and at bedtime. Diet: Calculated to 25 calories/kg/day (carbohydrates 45%, fat 37%, protein 18%, sodium <2300 mg/ day). (D) Supplemental insulin scale BG (mg/dl) software, version 21. Graphics were prepared with SigmaPlot software, version Results Insulin dose > a Insulin LM75/25, insulin lispro mix 75/25. BG, blood glucose; TDD, total daily dose. From March 25, 2014, to September 26, 2014, a total of 2670 patients were hospitalized in the Department of Cardiology. Of these, 54 patients who met the inclusion criteria provided consent. From this group, 27 patients were randomized to receive insulin LM75/25 and 27 patients to receive basal-plus regimen with glargine. After randomization, two patients from each group were excluded because they received <24 h of insulin treatment. A total of 25 patients in the insulin LM75/25 group and 25 patients in the basal-plus group were included in the final analysis. Clinical characteristics of the study patients are shown in Table 2. There were no significant differences between groups in mean age, sex, body mass index, duration of diabetes, glycated hemoglobin (HbA1c), and length of hospital stay. In both groups, each patient had an average of two comorbid conditions with similar distribution. The admitting diagnoses in the insulin LM75/25 group were ischemic heart disease (80%) and valvular heart disease (20%), whereas the basal-plus regimen diagnoses included ischemic heart disease (72%), cardiac arrhythmia (12%), auricular myxoma (8%), valvular heart disease (4%), and heart failure (4%). None of the patients had a history of nephropathy, neuropathy, or retinopathy. The mean admission glucose for the insulin LM75/25 group was mg/dl and in the basal-plus group was mg/dl (P = 0.235). Changes in glycemic control during the hospital stay are shown in Table 3. Both Variable Table 2. Clinical Characteristics of Study Patients Insulin LM75/25 Basal-plus P No. of patients Gender, n (%) a Male 18 (72) 14 (56) Female 7 (28) 11 (44) Age (years) b BMI (kg/m 2 ) b Duration of diabetes c (years) HbA1c (%) c Serum creatinine (mg/dl) c Diabetes treatment before admission, n (%) Insulin 4 (16) 5 (20) d Insulin plus oral agents 5 (20) 4 (16) d Oral agent monotherapy 2 (8) 5 (20) d Multiple oral agents 14 (56) 11 (44) a Comorbid conditions, n (%) Obesity/overweight 22 (88) 17 (68) a Hypertension 14 (56) 16 (64) a Previous ischemic 13 (52) 12 (48) a heart disease Dyslipidemia 8 (32) 10 (40) a Other 4 (16) 8 (32) d Admitting diagnoses, n (%) Ischemic heart disease 20 (80) 18 (72) a Valvular heart disease 5 (20) 1 (4) d Cardiac arrhythmia 0 3 (12) Auricular mixoma 0 2 (8) Heart failure 0 1 (4) Hospital stay (days) b a Comparison of proportions by v 2 test. b Comparison between medians by Mann Whitney U test. c Comparison between means by Student s t test for independent samples. d Comparison of proportions by Fisher exact test. BMI, body mass index; HbA1c, glycated hemoglobin.
4 708 GRACIA-RAMOS ET AL. Table 3. Glycemic Control, Insulin Therapy, and Hospital Complications in Patients Treated with Insulin Lispro Mix 72/25 (LM75/25) and Basal-Plus Regimen Insulin LM75/25 Insulin glargine P Glycemic control Admission BG (mg/dl) a BG reading during therapy (mg/dl) After the 1st day a After the 2nd day a After the 3rd day a After the 4th day a After the 5th day a After the 6th day a BG at follow-up (mg/dl) a BG range at follow-up, n (%) mg/dl 18 (72) 14 (56) b >140 mg/dl 7 (28) 11 (44) BG difference between the beginning and the end a of treatment (mg/dl) BG registered at different times of the day (mg/dl) Fasting BG <0.001 a,c Before lunch BG a,c Before dinner BG a Bedtime a,c Total dose of insulin (U/kg) <0.001 a,c Patients with hypoglycemia d Hypoglycemic events b a Comparison between means by Student s t test for independent samples. b Comparison of proportions by v 2 test. c Value with significance level (P = 0.05). d Comparison of proportions by Fisher exact test. treatment regimens resulted in prompt and sustained improvement in mean daily BG concentration during the hospital stay, showing similar improvement in daily BG after the first day of therapy but without significant difference (Fig. 1). The percentage of subjects who achieved a mean BG between 70 and 140 mg/dl was higher in the insulin LM75/25 group (72%) than in the basal-plus group (56%); however, the difference was not statistically significant (P = 0.239). The mean BG concentration at the end of follow-up was mg/dl in the insulin LM75/25 group and mg/dl in the basal-plus group, but without significant difference (P = 0.153). The difference between the mean admission glucose and the mean BG at follow-up was mg/dl in the insulin LM75/25 regimen and mg/dl in the basal-plus regimen. These results were significant for each group (both groups with P < 0.001) but not when compared between groups (P = 0.086). According to the BG registered at different times of the day, when analyzing each of the groups, there was no difference in mean glucose in the group treated with insulin LM75/25, whereas in the group treated with insulin glargine, the glucose reported at breakfast was lower than that recorded before lunch and bedtime (Fig. 2). Compared with insulin LM75/25, treatment with the basal-plus regimen was associated with lower BG before breakfast ( vs mg/dl, P < 0.001) but was higher before lunch ( vs mg/dl, P = 0.047) and bedtime ( vs mg/dl, P = 0.002). There was no difference in BG before dinner between groups ( mg/dl in the insulin LM75/25 group and mg/dl in the insulin glargine group, P = 0.536). Total daily dose of insulin (U/kg) was higher in the insulin LM75/25 group ( U/kg) than in the basal-plus group ( U/kg; P < 0.001). There was no difference in the supplemental doses of insulin lispro during the hospital stay in both groups. Hypoglycemia (BG <70 mg/dl) occurred in four patients (16%) in both groups (P = 0.649). Of the 568 glucose readings in the insulin LM75/25 group, there were seven (1.2%) glucose values <70 mg/dl, whereas in the 532 glucose readings in the basal-plus regimen, there were 10 (1.9%) glucose values <70 mg/dl (P = 0.529). In both groups, no glucose values <40 mg/dl were recorded. In all cases, hypoglycemia was corrected with oral dextrose and no episodes were associated with adverse outcomes. Discussion This is the first randomized prospective trial comparing the efficacy and safety of a premixed insulin analogue (insulin lispro mix 25, 75% insulin lispro protamine suspension, 25% lispro) with basal-plus regimen with insulin glargine once daily plus corrective doses with lispro before meals in hospitalized patients with T2D. We observed similar improvements in glycemic control in both groups with no differences in the mean daily BG, number of BG readings within aim of treatment, and number of hypoglycemic events. Hyperglycemia in hospitalized patients is a common, serious, and costly healthcare problem. 22 Evidence from observational and interventional studies indicates that hyperglycemia in critical and noncritical illness is associated with an increased risk of complications such as infections,
5 PREMIXED INSULIN ANALOGUE IN HOSPITAL SETTING 709 FIG. 1. Changes in mean daily blood glucose concentration between patients treated with insulin lispro mix 75/25 (LM75/ 25) and basal-plus regimen with glargine (mean standard error). prolonged hospital stay, disability after hospital discharge, and death Randomized clinical trials in critically ill and noncritically ill patients have reported that improved glycemic control can reduce the number of hospital complications Based on this, clinical guidelines from professional organizations recommend the use of subcutaneous insulin as the preferred therapy for glycemic control in hospitalized patients in a non-icu setting The most recommended regimen is the basal-bolus insulin therapy. However, this regimen requires subcutaneous administration of basal insulin once or twice daily in combination with prandial and corrective doses of rapid-acting insulin given before meals. The complexity of this approach has limited its acceptance among physicians Another scheme is the basal-plus regimen, which consists of a single daily dose of basal insulin with supplemental (corrective) doses of rapidacting insulin analogues before meals. This has a similar efficacy and safety as the basal-bolus regimen. 30,31 However, the basal-plus scheme does not provide prandial coverage of insulin. Therefore, we tested the use of insulin LM75/25 with the hypothesis that use of a premixed insulin analogue is a convenient insulin regimen by providing bolus insulin with meals through a rapid-action component and by fulfilling basal insulin requirements through a protaminated slower release component, and may represent an alternative to the use of the basal-plus regimen in hospitalized subjects with T2D. In the current study, we found that treatment with premixed insulin analogue resulted in similar glucose control as the basal-plus regimen with a prompt and sustained improvement in mean daily BG after the first day of therapy, with a BG aim <140 mg/dl in >70% of patients. These results are similar to those reported in other studies. The basal-plus trial compared the efficacy and safety of a daily dose of glargine plus corrective doses with glulisine before meals against a standard basal-bolus regimen and sliding scale regular insulin in medical and surgical patients with T2D. There was a significant improvement in mean daily BG after the first day of therapy in the intervention groups ( mg/dl for the basal-plus group and mg/dl for the basal-bolus group, P = NS). BG aim of <140 mg/dl was achieved in less than half of those groups. 30 A recent study by Bellido et al. compared the efficacy and safety of a premixed human insulin regimen (30% regular insulin and 70% NPH insulin) twice daily with basal-bolus regimen (glargine once daily and glulisine before meals) in medical and surgical patients with T2D and reported a mean daily BG level after the first day of insulin treatment of and in the premixed human insulin and basal-plus regimens, respectively, with a BG aim between 80 and 180 mg/dl achieved in 54.3% and 55.9%, respectively. 36 In other studies with the basal-bolus scheme, the mean daily BG level after the first day has been reported to range from 145 to 160 mg/ dl with a BG aim <140 mg/dl in a range from 45% to 76%. 15,21,22,25,37
6 710 GRACIA-RAMOS ET AL. FIG. 2. Comparison in the blood glucose registered at different times of the day between the insulin lispro mix 75/25 (LM7525) group and the basal-plus group with glargine (mean standard error). *P < Hypoglycemia is an undesirable side effect in hospitalized patients treated with insulin and has potentially harmful outcomes. 38 Hypoglycemia is also the leading limiting factor in improving glycemic control in patients with diabetes. 39 The incidence of hypoglycemia in noncritical patients treated with insulin has been reported to range from 0.2% to 64.1%. 15,21 25,30,36 In agreement with previous studies, 15,21,22,30 we show that the use of insulin LM75/25 is well tolerated with a low rate of hypoglycemia (BG <70 mg/dl in 16% of patients). There were no patients with severe hypoglycemia (BG <40 mg/dl). However, in the study by Bellido et al., hypoglycemia occurred in 64.1% of patients treated with premixed human insulin regimen during the hospital stay, which resulted in the interruption of the study according to their safety protocol (prespecified stopping rule of >50% of hypoglycemic events). 36 The higher rate of hypoglycemia with the use of premixed human insulin compared with the treatment with premixed insulin analogue in our study is likely the result of a higher dose of insulin ( U/kg for the premixed human insulin vs U/kg for the premixed insulin analogue). Furthermore, the pharmacokinetic profile of premixed insulin analogue has less intraindividual variability with a greater glucoselowering activity and lower risk of hypoglycemia than premixed human insulins Minimizing the rate of hypoglycemic events is of major importance in hospitalized patients because it has been shown to be an independent risk factor of poor clinical outcome. 38 With respect to the insulin dose used in our study, the dose received in the insulin LM75/25 group was similar to the conservative protocol used by Buchs et al. 23 and the insulin glargine dose was calculated according to the proportion of basal insulin received in the insulin LM75/25 group. In both treatment groups, the insulin dose was lower than that used in other studies, but the efficacy and safety in the two schemes was similar to those studies. 21,22,25,30,36,37 The lower insulin glargine dose perhaps also explains the lack of differences between groups and the higher value of glucose before lunch and dinner. However, our findings are similar to those found in the basal-plus trial, in which the basal-plus regimen used half of the insulin dose used in the basal-bolus scheme and both regimens resulted in similar glycemic control with a low rate of hypoglycemia. 30 An important point to consider for the application of insulin in a hospital setting is the changes in oral intake and insulin requirements. In individuals with lack of oral intake or fasting periods, administration of the basal-plus scheme may be preferable. However, if the patient is able to eat without difficulty and does not need fasting, administration of a premixed insulin analogue may be an option. We recognize several limitations to the study, including the relatively small number of patients recruited and the fact that the study was conducted in a single institution with patients only from a single clinical department. The study also excluded patients admitted to or expected to require ICU admission, patients undergoing cardiac surgery, those with
7 PREMIXED INSULIN ANALOGUE IN HOSPITAL SETTING 711 corticosteroid therapy, clinically relevant hepatic disease (Child Pugh score B or C) or impaired renal function (serum creatinine 2.0 mg/dl), and pregnant patients. We also excluded patients with severe hyperglycemia (>400 mg/dl) and patients who were receiving a total dose of insulin >0.4 U/kg/ day before admission. For such patients, higher insulin doses or a standard basal-bolus approach may be the preferred approach in achieving glycemic control. In addition, our study was not powered to determine differences in hospital complications across groups and the estimated sample size was possibly insufficient to measure the impact of secondary outcomes. A large, prospective, randomized multicenter clinical trial of glycemic control is certainly needed to address these important issues. These studies should include additional treatment regimens such as the use of basal-bolus regimen with analogue or human insulin and premixed human insulin. In summary, the results of our pilot study indicate that the inpatient use of a premixed insulin analogue (LM72/25) resulted in a similar improvement in glycemic control and hypoglycemic outcomes compared with the basal-plus regimen. These results indicate that premixed analogue insulin may be an effective alternative in the management of hyperglycemia in hospitalized patients with T2D. However, this result should be interpreted with caution because it included a relatively small number of patients. Further larger controlled studies are needed to validate these findings. Acknowledgments The authors thank the contribution of Dr. Joaquin Vargas Peñafiel, who collaborated in the conduction of this study, and Dr. Alejandro Correa Flores, who contributed with his expertise and knowledge. Also, the authors thank Nutritionist Luz Maria Graciela Cuellar Vazquez, for her close cooperation in the nutritional care of the patients. Author Disclosure Statement No competing financial interests exist. References 1. International Diabetes Federation: Diabetes Atlas, 7th ed. Brussels: International Diabetes Federation, (accessed January 5, 2016). 2. Van den Bergue G, Wilmer A, Milants I, et al.: Intensive insulin therapy in mixed medical/surgical intensive units: benefit versus harm. Diabetes 2006;55: Umpierrez GE, Isaacs SD, Bazargan N, et al.: Hyperglucemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002;87: McAllister FA, Majumdar SR, Blitz S, et al.: The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care 2005;28: Baker EH, Janaway CH, Philips BJ, et al.: Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 2006;61: Capes SE, Hunt D, Malmberg K, et al.: Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001;32: Kes VB, Solter W, Supanc V, Demarin V: Impact of hyperglycemia on ischemic stroke mortality in diabetic and non-diabetic patients. Ann Saudi Med 2007;27: Capes SE, Hunt D, Malmberg K, Gerstein HC: Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000;355: Falciglia M, Freyberg RW, Almenoff PL, et al.: Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Crit Care Med 2009;37: Kosiborod M, Inzucchi SE, Krumholz HM, et al.: Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation 2008;117: Kosiborod M, Inzucchi SE, Spertus JA, et al.: Elevated admission glucose and mortality in elderly patients hospitalized with heart failure. Circulation 2009;119: Furnary AP, Gao G, Grunkemeler GL, et al.: Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003;125: Van der Berghe G, Wilme A, Hermans G, et al.: Intensive insulin therapy in the medical UCI. N Engl J Med 2006; 354: Van den Berghe G, Wouters P, Weekers F, et al.: Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: Umpierrez GE, Smiley D, Jacobs S, et al.: Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011;34: Umpierrez GE, Hellman R, Korytkowski MT, et al.: Management of hyperglucemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012;97: American Diabetes Association: Standards or medical care in diabetes Diabetes Care 2016;39(Suppl. 1):S99 S Moghissi ES, Korytkowski MT, DiNardo M, et al.: American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract 2009;15: Roberts GW, Aguilar-Loza N, Esterman A, et al.: Basalbolus insulin versus sliding-scale insulin for inpatients glycaemic control: a clinical practice comparison. Med J Aust 2012;196: Zaman Huri H, Permalu V, Vethakkan SR: Sliding-scale versus basal-bolus insulin in the management of several or acute hyperglycemia in type 2 diabetes patients: a retrospective study. PloS One 2014;9:e Umpierrez GE, Smiley D, Zisman A, et al.: Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007;30: Umpierrez GE, Hor T, Smiley D, et al.: Comparison of inpatient insulin regimens with determir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94: Buchs AE, Bloemers R, Shiloah E, et al.: Feasibility and safety of multiple daily insulin injections in general medicine wards. Eur J Intern Med 2009;20:
8 712 GRACIA-RAMOS ET AL. 24. Meyer C, Boron A, Plummer E, et al.: Glulisine versus human regular insulin in combination with glargine in noncritically ill hospitalized patients with type 2 diabetes. Diabetes Care 2010;33: Vellanki P, Bean R, Oyedokun FA, et al.: Randomized controlled trial of insulin supplementation for correction of bedtime hyperglycemia in hospitalized patients with type 2 diabetes. Diabetes Care 2015;38: Umpierrez G, Maynard G: Glycemic chaos (not glycemic control) still the rule for inpatient care: how do we stop the insanity? J Hosp Med 2006;1: Cook CB, Castro JC, Schmidt RE, et al.: Diabetes care in hospitalized noncritically ill patients: more evidence for clinical inertia and negative therapeutic momentum. J Hosp Med 2007;2: Shnipper JL, Barsky EE, Shaykevich S, et al.: Inpatient management of diabetes and hyperglycemia among general medicine patients at a large teaching hospital. J Hosp Med 2006;1: Wexler DJ, Meigs JB, Cagliero E, et al.: Prevalence of hyper- and hypoglycemia among inpatients with diabetes. Diabetes Care 2007;30: Umpierrez GE, Smiley D, Hermayer K, et al.: Randomized study comparing a basal bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes. Diabetes Care 2013;36: Smiley D, Umpierez GE, Hermayer K, et al.: Differences in inpatient glycemic control and response to subcutaneous insulin therapy between medicine and surgery patients with type 2 diabetes. J Diabetes Complications 2013;27: Buse JB, Wolfffenbuttel BHR, Herman WH, et al.: The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine. Diabetes Care 2011;34: Bowerin K, Reed VA, Felicio J, et al.: A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study. Diabet Med 2012;29: e263 e Qayyum R, Bolen S, Maruthur N, et al.: Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 2008;149: Jia W, Xiao X, Ji Q, et al.: Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomized, controlled trial. Lancet Diabetes Endocrinol 2015;3: Bellido V, Suarez L, Rodriguez MG, et al.: Comparison of basal-bolus and premixed insulin regimens in hospitalized patients with type 2 diabetes. Diabetes Care 2015;38: Bueno E, Benitez A, Rufinelli JV, et al.: Basal-bolus regimen with insulin analogues versus human insulin in medical patients with type 2 diabetes: a randomized controlled trial in Latin America. Endocr Pract 2015;21: Eiland L, Goldner W, Drincic A, Desouza C: Inpatient hypoglycemia: a challenge that must be addressed. Curr Diab Rep 2014;14: Ben-Ami H, Nagachandran P, Mendelson A, Edoute Y: Drug-induced hypoglycemic coma in 102 diabetic patients. Arch Intern Med 1999;159: Rolla A: Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety. Am J Med 2008;121(Suppl. 6):S9 S Mooradian AD, Bernbaum M, Albert SG: Narrative review: a rational approach to starting insulin therapy. Ann Intern Med 2006;145: Martorella AJ: Iatrogenic hypoglycemia in patients with type 2 diabetes: comparison of insulin analog premixes and human insulin premixes. Postgrad Med 2011;123:7 16. Address correspondence to: Abraham Edgar Gracia-Ramos, MD, MSc Departamento de Medicina Interna Hospital de Especialidades Centro Médico Nacional La Raza Instituto Mexicano del Seguro Social Mexico. Seris y Zaachila S/N, Col. La Raza Del. Azcapotzalco, C.P Cuidad de México México aegr_1982@outlook.com
Transition of Care in Hospitalized Patients with Hyperglycemia and Diabetes
Transition of Care in Hospitalized Patients with Hyperglycemia and Diabetes Critically ill patients in the ICU Hospital Non-ICU Settings Home Guillermo E Umpierrez, MD, FACP, FACE Professor of Medicine
More informationHAP PA-HEN Achieving More Together
HAP PA-HEN Achieving More Together Managing Hyperglycemia in the Hospital: Strategies for Safe and Effective Care Pennsylvania Patient Safety Authority Managing Hyperglycemia in the Hospital: Strategies
More informationHow to manage type 2 diabetes in medical and surgical patients in the hospital
MEDICAL GRAND ROUNDS CME CREDIT EDUCATIONAL OBJECTIVE: Readers will learn the relationship between glycemic control and clinical outcomes in hospitalized medical and surgical patients who are not in an
More informationManagement of Inpatient Hyperglycemia: 2011 Endocrine Society Meeting Hyperglycemia in Critically ill patients in ICU Settings.
Management of Inpatient Hyperglycemia: 2011 Endocrine Society Meeting Guillermo E. Umpierrez, MD, Emory University School of Medicine and Jack Leahy, MD, University of Connecticut Hyperglycemia in Critically
More informationComparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary
Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions
More informationprolonged hospital stay, infections, and disability after hospital discharge, and death (1 3). Several clinical trials in
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Randomized Study Comparing a Basal Bolus With a Basal Plus Correction Insulin Regimen for the Hospital Management of
More informationEvidence for Basal Bolus Insulin Versus Slide Scale Insulin
Curr Emerg Hosp Med Rep (2014) 2:26 34 DOI 10.1007/s40138-013-0032-4 DIABETES AND METABOLIC DISEASE (W FORD, SECTION EDITOR) Evidence for Basal Bolus Insulin Versus Slide Scale Insulin Sameer Badlani William
More informationSection of Endocrinology, Rush University Medical Center, Chicago, Illinois.
ORIGINAL RESEARCH Treatment of Inpatient Hyperglycemia Beginning in the Emergency Department: A Randomized Trial Using Insulins Aspart and Detemir Compared With Usual Care Jennifer B. Bernard, MD Christina
More informationInpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, :30 a.m. 11:15 a.m.
Inpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 1, 218 1:3 a.m. 11:15 a.m. There are over 7.5 million hospital admissions for patients with diabetes in the US. About
More informationInpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, :30 a.m. 11:15 a.m.
Inpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, 2018 10:30 a.m. 11:15 a.m. There are over 7.5 million hospital admissions for patients with diabetes in the US.
More information123 Are You Providing Evidence-Based Diabetes Care? - Martin
Donna Martin, DNP, RN, CDE, CMSRN Lewis University Learner will be able to: Identify current inpatient standards of care for patients with diabetes Describe causes of hyperglycemia / hypoglycemia in the
More informationΑναγκαιότητα και τρόπος ρύθμισης του διαβήτη στους νοσηλευόμενους ασθενείς
Αναγκαιότητα και τρόπος ρύθμισης του διαβήτη στους νοσηλευόμενους ασθενείς Αναστασία Θανοπούλου Επίκουρη Καθηγήτρια Β Παθολογικής Κλινικής Πανεπιστημίου Αθηνών Διαβητολογικό Κέντρο, Ιπποκράτειο Νοσοκομείο
More informationInpatient and perioperative management of hyperglycemia
Inpatient and perioperative management of hyperglycemia Department of Internal Medicine Grand Rounds July 7, 2017 Luigi Meneghini discloses that he has served on advisory boards and as consultant for both
More informationMeeting the Challenge of Inpatient Glycemic Management in the Non-Critical Care Setting
Meeting the Challenge of Inpatient Glycemic Management in the Non-Critical Care Setting Jane Jeffrie Seley, DNP, MPH, GNP, BC-ADM, CDE, CDTC, FAAN, FAADE Diabetes Nurse Practitioner, Inpatient Diabetes
More informationInpatient Diabetes Management: The Slippery Slope of Sliding Scale Insulin
Inpatient Diabetes Management: The Slippery Slope of Sliding Scale Insulin David Newman, MD University of North Dakota School of Medicine Sanford Health Big Sky Conference 2017 Dr. David Newman, Personal/Professional
More informationInpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy
Inpatient Management of Diabetes Mellitus Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy 2 Disclosure Jessica Garza does not have any actual or potential conflicts of
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationDeepika Reddy MD Department of Endocrinology
Deepika Reddy MD Department of Endocrinology Management of hyperglycemic crisis Review need for inpatient glycemic control Brief overview of relevant trials Case based review of diabetes management strategies/review
More information5/15/2018 DISCLOSURE OBJECTIVES. FLORIDA HOSPITAL ORLANDO Not for profit organization Acute care medical center 1,368 licensed beds BACKGROUND
DISCLOSURE PHARMACIST DIRECTED MANAGEMENT OF GLUCOCORTICOID INDUCED HYPERGLYCEMIA AT A LARGE COMMUNITY HOSPITAL Jill Zaccardelli, PharmD PGY1 Pharmacy Resident Florida Hospital Orlando Jill.Zaccardelli@flhosp.org
More informationGlycemic Control Insulin In The Hospital Setting
Glycemic Control Insulin In The Hospital Setting Glycemic Control The Evidence For Insulin s s Benefit The Mechanism of Insulin s s Benefit The Achievement of Insulin s s Benefit A Few Cases Hyperglycemia
More information9/23/09. What are the key components of preoperative, intraoperative, & postoperative care of diabetes management? Rebecca L. Sturges, M.D.
RMHS Perioperative Summit: Perioperative Diabetes Management Rebecca L. Sturges, M.D. Oct 6, 2009 Mrs. B was referred by her orthopedic surgeon to your preoperative clinic to discuss medical management
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationNormal glucose values are associated with a lower risk of mortality in hospitalized patients
Diabetes Care Publish Ahead of Print, published online August Hyperglycemia 20, 2008 in hospital Normal glucose values are associated with a lower risk of mortality in hospitalized patients Alberto Bruno
More informationAPPENDIX American Diabetes Association. Published online at
APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no
More informationA Children s Bedtime Story
A Children s Bedtime Story Setting: University Medical Center, Big Town, USA Scenario: 0500, last admission of the night, 10 previous admissions, all tucked in for the night Patient: 75 year old male with
More information4/10/2015. Foundations to Managing Inpatient Hyperglycemia. Learning Objectives
Foundations to Managing Inpatient Hyperglycemia Module A 1 Learning Objectives Develop strategies to identify patients with hyperglycemia or diabetes in the inpatient setting Establish glycemic goals to
More informationIntravenous insulin aspart in a hospital setting: results from an observational study examining patient outcomes and physician preferences
Research article Intravenous insulin aspart in a hospital setting: results from an observational study examining patient outcomes and physician preferences Summary Points Farokh Udwadia, Arpandev Bhattacharyya2,
More informationSafety and Efficacy of Continuous Insulin Infusion in Noncritical Care Settings
ORIGINAL RESEARCH Safety and Efficacy of Continuous Insulin Infusion in Noncritical Care Settings Dawn Smiley, MD 1 Mary Rhee, MD 1 Limin Peng, PhD 2 Laurian Roediger, BS 1 Patrick Mulligan, BS 1 Lewis
More informationIn-Hospital Management of Diabetes
In-Hospital Management of Diabetes Clinical order sets guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Table of Contents Key elements from the Canadian Diabetes Association 2013 Clinical Practice
More informationParenteral Nutrition The Sweet and Sour Truth. From: Division of Endocrinology, Diabetes and Bone Disease Icahn School of Medicine at Mount Sinai
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationInpatient Glycemic Management 2016
2016 Jim Chamberlain MD Medical Director for Diabetes Services St. Mark s Hospital and St. Mark s Diabetes Center Salt Lake City, Utah Disclosures Speakers Bureaus Merck & Co. Janssen Pharmaceutical Companies
More informationManagement of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting:
T h e E n d o c r i n e S o c i e t y s Clinical Guidelines Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline Authors:
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationNOT-SO-SWEET! THE STRAIGHT SCOOP ON DIABETES IN THE HOSPITAL SETTING
Sharp HealthCare s 2016 Diabetes Conference November 11, 2016 NOT-SO-SWEET! THE STRAIGHT SCOOP ON DIABETES IN THE HOSPITAL SETTING Tamara Swigert, MSN, RN, CDE Speaker Disclosure Tammy Swigert has no conflicts
More informationBasal Bolus Insulin Therapy Frequently Asked Questions
1. What is Basal Bolus Insulin Therapy (BBIT)? 2. What evidence supports the use of subcutaneous Basal Bolus Insulin Therapy? 3. Does Basal Bolus Insulin Therapy apply to all patients? 4. What s wrong
More informationWhat s so sweet about glycemic control? June 3, 2016
What s so sweet about glycemic control? June 3, 2016 Objectives Provide an overview of why glucose control is important in surgical patient outcomes. Demonstrate an understanding of how anesthetics and
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationIndividualising Insulin Regimens: Premixed or basal plus/bolus?
Individualising Insulin Regimens: Premixed or basal plus/bolus? Dr. Ted Wu Director, Diabetes Centre, Hospital Sydney, Australia Turkey, April 2015 Centre of Health Professional Education Optimising insulin
More informationAkio Ohta, Kaori Arai, Ami Nishine, Yoshiyuki Sada, Hiroyuki Kato, Hisashi Fukuda, Shiko Asai, Yoshio Nagai, Takuyuki Katabami and Yasushi Tanaka
Endocrine Journal 2013, 60 (2), 173-177 Or i g i n a l Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationDisclosures. Glycemic Control in the Intensive Care Unit. Objectives. Hyperglycemia. Hyperglycemia. History. No disclosures
Disclosures Glycemic Control in the Intensive Care Unit No disclosures Jorie Frasiolas, Pharm.D., BCPS Clinical Pharmacy Manager, CTICU NewYork-Presbyterian Hospital Columbia University Medical Center
More informationDEMYSTIFYING INSULIN THERAPY
DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING
More informationInsulin Order Sets & In-Hospital Management of Diabetes
Insulin Order Sets & In-Hospital Management of Diabetes 416591 Table of Contents Key elements from Diabetes Canada 2018 Clinical Practice Guidelines Introduction........................................................
More informationImproving Glycemic Control and Insulin Ordering Efficiency for Hospitalized Patients With Diabetes Through Carbohydrate Counting
e1 Improving Glycemic Control and Insulin Ordering Efficiency for Hospitalized Patients With Diabetes Through Carbohydrate Counting Kristina K. Pearson, Sarah A. Reiland, John G. O Meara, Julie K. Brown,
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationIn Hospital Management of Diabetes Mellitus
C H A P T E R 46 In Hospital Management of Diabetes Mellitus Jothydev Kesavadev INTRODUCTION Diabetes and its complications are a major cause of hospitalizations. Number of diabetes related deaths in India
More informationOptimizing Care of the Inpatient with Hyperglycemia and Diabetes: Case Studies in Action
Optimizing Care of the Inpatient with Hyperglycemia and Diabetes: Case Studies in Action Learning Objectives Identify patient situations where specific attention to glycemic control is warranted Determine
More informationManaging Diabetes and Hyperglycemia Safely in the Complex Hospital Setting
Managing Diabetes and Hyperglycemia Safely in the Complex Hospital Setting Greg Maynard MD, MSc Clinical Professor of Medicine and CQO, UC Davis Medical Center Sacramento, CA Greg Maynard Disclosure SHM
More informationnocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded
Clinical Trial Design/ Primary Objective Insulin glargine Treat-to-Target Trial, Riddle et al., 2003 (23) AT.LANTUS trial, Davies et al., 2005 (24) INSIGHT trial, Gerstein et al., 2006 (25) multicenter,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationIS THERE A "JULY EFFECT" FOR INPATIENT GLYCEMIC CONTROL?
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationMartin J Stevens MD, FRCP, Endocrinologist and Professor of Medicine
The Approach to Inpatient Hyperglycemia Martin J Stevens MD, FRCP, Endocrinologist and Professor of Medicine Great Lakes Hospital Medical Symposium May 7th 2010 Further Increases in the Prevalence of Diabetes
More informationWelcome Everyone. Monitoring, Sick Days, Inpatient Management - Objectives. Mrs. Jones has new diabetes. She asks you: Page 1
Welcome Everyone Sign-In Enjoy Breakfast Meet someone new Enter Raffle Pick a team name Please silence phones We start at 8:00am Monitoring, Sick Days, Inpatient Management - Objectives Objectives: Strategies
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationMANAGEMENT OF HYPERGLYCEMIA IN CRITICALLY ILL SURGICAL (NON-CARDIAC) PATIENTS
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationHow to Manage Steroid Diabetes in the Patient With Cancer David S. Oyer, MD, FACE, Ajul Shah, BS, and Susan Bettenhausen, APRN, CDE
H O W W E D O I T How to Manage Steroid Diabetes in the Patient With Cancer David S. Oyer, MD, FACE, Ajul Shah, BS, and Susan Bettenhausen, APRN, CDE G lucocorticosteroids (steroids) have profound effects
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationImplementing Glucose Control in 2009 and Beyond: Changes in Patterns and Perceptions
Implementing Glucose Control in 2009 and Beyond: Changes in Patterns and Perceptions Charles C. Reed MSN, RN, CNRN Patient Care Coordinator Surgical Trauma ICU University Hospital San Antonio, Texas Relationships
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationIn - Hospital Diabetes Care. A review and personal experience
In - Hospital Diabetes Care A review and personal experience Hyperglycemia in the Hospital The Problem Hospitalizations with Diabetes http://www.cdc.gov/diabetes/statistics/dmany/fig1.htm Prevalence of
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationACUTE ABDOMEN IN DIABETIC PATIENTS ANALYSIS OF COMPLICATIONS AND MORTALITY
2014 ILEX PUBLISHING HOUSE, Bucharest, Roumania http://www.jrdiabet.ro Rom J Diabetes Nutr Metab Dis. 21(4):277-284 doi: 10.2478/rjdnmd-2014-0034 ACUTE ABDOMEN IN DIABETIC PATIENTS ANALYSIS OF COMPLICATIONS
More informationWhat Should Be the Therapeutic Glycemic Target in Intensive Care Units?
What Should Be the Therapeutic Glycemic Target in Intensive Care Units? Irl B. Hirsch, M.D. Professor of Medicine University of Washington School of Medicine Disclosures Research/Grants: Sanofi, Halozyme
More informationBrigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol
Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients
More informationReceived: 23 September Accepted: 17 October 2009
ORIGINAL ARTICLE Comparing Effects of Continuous Insulin Infusion with or without Subcutaneous Glargine Insulin on Glycemic Control in Diabetic Patients Undergoing Coronary Artery Bypass Graft (CABG) Seyed
More informationOptimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes
Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes Philip Raskin, MD Professor of Medicine The University of Texas, Southwestern Medical Center NAMCP Spring
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationDisclosure. Disclosure. Disclosure. Course Outline. Objectives. A Touch of Sugar : Controlling Hyperglycemia in Acute Care Settings 7/25/2013
47 th Annual Meeting August 2-4, 2013 Orlando, FL A Touch of Sugar : Controlling Hyperglycemia in Acute Care Settings Kevin Forbush, Pharm. D Central Maine Medical Center Lewiston, Maine Disclosure I do
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationINSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital
INSULIN THERAPY Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 3 Sep. 2013 Case Somsak is a 64-year-old man was diagnosed with T2DM, HT, and dyslipidemia 9 years ago. No history of hypoglycemia
More informationPerioperative Management of the Patient with Endocrine Disease: A Focus on Diabetes & Thyroid Dysfunction
Perioperative Management of the Patient with Endocrine Disease: A Focus on Diabetes & Thyroid Dysfunction Luigi Meneghini, MD, MBA Professor, Internal Medicine (Endocrinology), UT Southwestern Medical
More informationComparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes DOI: /dc
Diabetes Care 1 Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes DOI: 10.2337/dc15-0160 Virginia Bellido, 1 Lorena Suarez, 1 Maria Galiana Rodriguez,
More informationStarting and Helping People with Type 2 Diabetes on Insulin
Starting and Helping People with Type 2 Diabetes on Insulin Elaine Cooke, BSc(Pharm), RPh, CDE Pharmacist and Certified Diabetes Educator Maple Ridge, BC Objectives After attending this session, participants
More informationEffect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPDresp_
ORIGINAL ARTICLE Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPDresp_1781 918..922 ALI PARAPPIL, 1 BARBARA DEPCZYNSKI, 2 PETER COLLETT
More informationInpatient diabetes mellitus: Institutional progress in management of an emerging hospital epidemic
Diabetes Management Inpatient diabetes mellitus: Institutional progress in management of an emerging hospital epidemic Bithika M. Thompson 1, M hamed Temkit 2, Janna C. Castro 3, Toni R. Yubeta 4, RN Heidi
More informationFINANCIAL IMPLICATIONS OF GLYCEMIC CONTROL: RESULTS OF AN INPATIENT DIABETES MANAGEMENT PROGRAM
ACE/ADA Inpatient Diabetes and Glycemic Control Consensus Conference FINANCIAL IMPLICATIONS OF GLYCEMIC CONTROL: RESULTS OF AN INPATIENT DIABETES MANAGEMENT PROGRAM Christopher A. Newton, MD, 1 and Sandra
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationThe Art and Science of Infusion Nursing Gwen Klinkner, MS, RN, APRN, BC-ADM, CDE
The Art and Science of Infusion Nursing Gwen Klinkner, MS, RN, APRN, BC-ADM, CDE The Importance of Glycemic Control in the Hospital and the Role of the Infusion Nurse ABSTRACT Diabetes is reaching epidemic
More informationPosition Statement of ADA / EASD 2012
Management of Hyperglycemia in Type2 Diabetes: A Patient- Centered Approach Position Statement of ADA / EASD 2012 Cause of : Type 2 diabetes Cardiovascular disorders Blindness End-stage renal failure Amputations
More informationANNUAL MEETING 2 #FSHP2017
FSHP Disclosure Strategies for Glycemic Management in the Inpatient Setting: Guidelines vs. Reality Melissa Marshall, PharmD, BCPS Jeffrey Ruff, PharmD We do not have (nor does any immediate family member
More informationSafety and Effectiveness of a Computerized Subcutaneous Insulin Program to Treat Inpatient Hyperglycemia
Journal of Diabetes Science and Technology Volume 2, Issue 3, May 2008 Diabetes Technology Society SYMPOSIUM Safety and Effectiveness of a Computerized Subcutaneous Insulin Program to Treat Inpatient Hyperglycemia
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationStroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols. Askiel Bruno, MD, MS Protocol PI
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols Askiel Bruno, MD, MS Protocol PI SHINE Synopsis Acute ischemic stroke
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationEffective Health Care Program
Comparative Effectiveness Review Number 57 Effective Health Care Program Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness Executive Summary Background Diabetes mellitus is
More informationType 2 Diabetes Mellitus Insulin Therapy 2012
Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration
More informationSelf-Monitoring Blood Glucose (SMBG) Frequency & Pattern Tool
Self-Monitoring Blood Glucose () Pattern Recommendation: Basal Insulin Only (To Target) NPH or long-acting analogue, typically given at. at least as often as is being given. Optional, less frequent can
More informationTargeting Glycemic Control in Non-Critically Ill Patients at a Tertiary Teaching Hospital. Brian Gilbert, Pharm.D. PGY-1 Pharmacy Resident
Targeting Glycemic Control in Non-Critically Ill Patients at a Tertiary Teaching Hospital Brian Gilbert, Pharm.D. PGY-1 Pharmacy Resident Objectives Discuss rationale for the development of a glycemic
More informationJanuary 7, 5:00 p.m. EST
Study 3-151 Phase 2 Trial: Preliminary Results BIOD-531, a Concentrated Ultra-Rapid-Acting Prandial/Basal Insulin, Demonstrates Superior Post-Meal Glucose Control Compared to Marketed Prandial/Basal Insulins
More informationThe following slides will provide evidence or support for the possible right answer(s) and/or clinical assessment/calculations
1 2 3 The following slides will provide evidence or support for the possible right answer(s) and/or clinical assessment/calculations 4 The following criteria are used to diagnose diabetes a) fasting plasma
More informationDATE: 12 January 2017 CONTEXT AND POLICY ISSUES
TITLE: Basal-Bolus Versus Sliding-Scale Insulin Therapy in the Acute Care Hospital Setting: A Review of Comparative Clinical Effectiveness and Cost-Effectiveness DATE: 12 January 2017 CONTEXT AND POLICY
More informationInsulin Intensification: A Patient-Centered Approach
MARTIN J. ABRAHAMSON, MD Harvard Medical School, Boston, MA Insulin Intensification: A Patient-Centered Approach Dr Abrahamson is associate professor of medicine at Harvard Medical School and medical director
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationInpatient Glycemic Management:
Disclosure to Participants Conflict of Interest (COI) and Financial Relationship Disclosures: Dr. Seley attended Advisory Board Meeting: Alliance (Boehringer-Ingelheim/Lilly) Bayer Diabetes Care Sanofi
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationCurrent Controversies in Diabetes Control
Current Controversies in Diabetes Control Dara P. Schuster, MD, FACE ADA, AACE/ACE, and ACP Guidelines: Treatment Goals for A1C, FPG, and PPG Parameter Normal 1,2 Level ADA 3 Goal AACE/ACE 2 Goal ACP 4
More informationEvolving insulin therapy: Insulin replacement methods and the impact on cardiometabolic risk
Evolving insulin therapy: Insulin replacement methods and the impact on cardiometabolic risk Harvard/Joslin Primary Care Congress for Cardiometabolic Health 2013 Richard S. Beaser, MD Medical Executive
More information